OIE Reference Laboratory Reports ActivitiesActivities in 2021

This report has been submitted: 2022-01-19 12:44:29

| Name of disease (or topic) for which you are a designated OIE Reference Laboratory: | Newcastle disease |
|--|---|
| Address of laboratory: | Animal and Plant Health Agency New Haw Addlestone Surrey KT15 3NB Weybridge UNITED KINGDOM |
| Tel.: | +44 208 026 9680 |
| Fax: | |
| E-mail address: | ian.brown@apha.gov.uk |
| Website: | https://www.gov.uk/government/organisations/animal-and-plant-health-agency |
| Name (including Title) of Head of Laboratory (Responsible Official): | Mr Ian Hewett , Acting Chief Executive |
| Name (including Title and Position) of OIE Reference Expert: | Professor Ian Brown Director of OIE/FAO International Reference Laboratory for Avian Influenza, Newcastle Disease and Swine Influenza |
| Which of the following defines your laboratory? Check all that apply: | Governmental |

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test | Indicated in OIE Manual (Yes/No) | Total number of test performed last year | |
|---|--|--|-----------------|
| Indirect diagnostic tests | | Nationally | Internationally |
| н | Yes | 3663 | 0 |
| Direct diagnostic tests | | Nationally | Internationally |
| Real-time RT-PCR L gene | Yes | 4880 | 87 |
| Real-time PCR RT-PCR for pathotyping | No | 0 | 30 |
| NDV genetic analysis by Sanger sequencing | Yes | 17 | 0 |
| Next Generation Sequencing | Yes | 1 | 10 |
| ICPI | Yes | 0 | 0 |
| Egg inoculation/HA | Yes | 1229 | 15 |

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.

To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

| Type of reagent available | Related diagnostic test | Produced/ provide | Amount supplied nationally (ml, mg) | Amount supplied internationally (ml, mg) | No. of recipient OIE Member Countries | Region of recipients |
|---------------------------|-------------------------------|----------------------|--|--|---|----------------------|
| Antisera | НІ | Provide | 22ml | 50.5ml | 4 | |
| Antigen | HI | Provide | 88ml | 157ml | 5 | |

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

| Name of OIE Member Country seeking assistance | Date (month) | No. samples received for provision of diagnostic support | No. samples received for provision of confirmatory diagnoses |
|---|--------------|--|--|
| GEORGIA | 1/21 | 0 | 24 |
| KAZAKHSTAN | 1/21 | 0 | 73 |
| BANGLADESH | 4/21 | 2348 | 0 |
| NORTH MACEDONIA (REP. OF) | 7/21 | 15 | 0 |

 $^{9. \ \, \}text{Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?}$

Yes

| Name of the OIE Member Country receiving a technical consultancy | Purpose | How the advice was provided |
|--|---------------------|-----------------------------|
| ETHIOPIA | Offer of assistance | Email |
| MALI | Offer of assistance | Email |
| TAJIKISTAN | Offer of assistance | Email |
| GUINEA | Offer of assistance | Email |
| COTE D'IVOIRE | Offer of assistance | Email |
| TANZANIA | Offer of assistance | Email |
| GHANA | Offer of assistance | Email |
| PAKISTAN | Offer of assistance | Email |
| BANGLADESH | Offer of assistance | Email |
| BOTSWANA | Offer of assistance | Email |

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

| Title of the study | Duration | Purpose of the study | Partners (Institutions) | OIE Member Countries involved other than your country |
|--|-----------|---|--|---|
| Kazakhstan OIE Twinning on Al and ND | 2019-2022 | The Twinning Project's goal is to enhance the technical expertise and skills of the Candidate Institute's personnel and demonstrate that it possesses the competency required of an OIE reference laboratory for Avian Influenza and Newcastle disease. | Kazakh Scientific Research Veterinary Institute, Almaty KazSRVI | KAZAKHSTAN |
| Turkey STEP LEIDOS training project cancelled because of COVID travel restrictions. Currently trying to reschedule for 2022. | 2019-2021 | The goal of the training is both training of staff in OIE methodologies and both wet laboratory training and data analysis. THE activities also include technology transfer to the linked laboratory in Turkey. | Bornova Veterinary Control Institute, Turkey. | TURKEY |
| MoD Central Asian Hub- concept developed with funder invitation extended; OIE regional office supporting | 2019-2022 | To work off the back of the OIE twinning project with Kazakhstan and To develop a network of collaborative labs across Central Asia for the detection and diagnosis of NDV | The project initiation will involve a one- day webinar involving laboratory representatives from: Kazakhstan Tajikistan Turkmenistan Afghanistan Uzbekistan Kyrgystan And the UK LInkage with Dr. Mereke Taitubayev Head of OIE Sub Regional Office for Central Asian Руководитель Субрегионального офиса МЭБ по Центральной Азии Republic Avenue 50/1 010000 Nur-Sultan, Republic of Kazakhstan | |

| DTRA BAA Kurdistan to undertake One Health integrated biosurveillance and poultry value chain analyses to assist Kurdistan into international AIV and ND surveillance and research. developed with funder invitation extended; OIE regional office supporting DTRA BAA Kurdistan to undertake One Health integrated biosurveillance and poultry value chain analyses to assist Kurdistan into international AIV and ND surveillance and research. | 2019-2022 | Extensive co- ordination among consortium partners to define workplan and write white paper application for funding throughout 2020. | Kurdistan Institution for Strategic Studies and Scientific Research (KISSR) through Nabil Ali Wali Logistics support through CDRF | IRAN |
|---|-----------|---|--|------|
|---|-----------|---|--|------|

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

Genetic sequencing and characterisation of viruses circulating in a range of countries requesting assistance.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

Genetic sequencing and characterisation of viruses circulating in a range of countries requesting assistance.

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 4
Hisanaga T; Soos C; LEWIS N; Lung O; Suderman M; Berhane Y (2021)
Genetic and antigenic characterization of avian avulavirus type 6 (AAvV-6) circulating in Canadian wild birds (2005-2017).

Viruses 13 (4) 543.

https://doi.org/10.3390/v13040543

Ian H. Brown, Peter Cargill, Ralph Woodland and Thierry Van den Berg. Newcastle disease virus IN Veterinary Vaccine for Livestock, 1st Edition: Editors; Samia Metwally, Ahmed Elldrissi, Gerrit Viljoen. John Wiley and Sons, UK (published July 2021) ISBN: 978-1-119-50595-2

lan H Brown; Newcastle Disease: IN Poultry Health: A Guide for Professionals - Ch. 15viii CABI http://dx.doi.org/10.1079/9781789245042.0015

I.H.Brown, M.J.Slomka, C.A. Cassar, L.M.Mcelhinney, & A.Brouwer IN PRESS The role of national and international veterinary laboratories Chapter 10 In Diagnostic test validation science: a key element for effective detection and control of infectious animal diseases", OIE Scientific and Technical Review

b) International conferences: 3

A Banyard. 2021. International Scientific and Practical Conference "Modern ways of preventing the most common infectious and invasive diseases of animals" July 23, Tajik Academy of Agricultural Sciences, Rudaki Avenue 21a, Dushanbe

A Banyard, I Brown, N. Lewis- Meeting on the formation of Avian influenza and Newcastle disease diagnosis and surveillance subnetwork- OIE International Workshop organised by A Banyard and OIE regional representatives and involving presentations from all Central Asian countries. Avian Influenza and Newcastle disease network - OIE - Europe

lan Brown; The drivers of emergence and spread of avian disease epidemics. Towards a New Mindset for Epidemic Diseases; Berbetos Seminar 1/9/21

- c) National conferences: 0
- d) Other:

(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Nο

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

| Quality management system adopted | Certificate scan (PDF, JPG, PNG format) |
|-----------------------------------|---|
| ISO/IEC 17025:2017 | ISO-IEC 17025-2017a.pdf |

16. Is your quality management system accredited?

Yes

| Test for which your laboratory is accredited | Accreditation body |
|--|--------------------|
| Haemagglutination inhibition test | UKAS |
| L-gene real-time PCR | UKAS |
| Newcastle disease virus nucleotide sequencing (Sanger) | UKAS |
| ICPI | UKAS |
| Virus isolation in tissue culture for APMV-1 | UKAS |
| Virus isolation in SPF eggs (via allantoic cavity) | UKAS |
| Antibody typing of ND isolates | UKAS |
| Next Generation Sequencing | UKAS |

 $17. \ \mathsf{Does} \ \mathsf{your} \ \mathsf{laboratory} \ \mathsf{maintain} \ \mathsf{a} \ \mathsf{``biorisk} \ \mathsf{management} \ \mathsf{system''} \ \mathsf{for} \ \mathsf{the} \ \mathsf{pathogen} \ \mathsf{and} \ \mathsf{the} \ \mathsf{disease} \ \mathsf{concerned?}$

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories

designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

| Purpose of the proficiency tests: 1 | Role of your Reference Laboratory (organiser/ participant) | No. participants | Participating OIE Ref. Labs/ organising OIE Ref. Lab. |
|-------------------------------------|---|---------------------|--|
| EURL Proficiency test | Participant | 40 | All EU members states, Belarus, Bosnia and Herzegovina, Montenegro, Norway, Russia, Serbia, Switzerland, North Macedonia, Turkey, Ukraine, UK |

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

| Purpose for inter-laboratory test comparisons ¹ | No. participating laboratories | Region(s) of participating OIE Member Countries |
|---|-----------------------------------|--|
| PT exercise (extended to other OIE member countries) Conventional (antigen and serum) and molecular panels for NRLs | 31 | ⊠Africa □Americas ⊠Asia and Pacific ⊠Europe ⊠Middle East |

ToR 12: To place expert consultants at the disposal of the OIE

| 24. Did y | our laborator | y place expert | consultants at | the disposa | I of the OIE? |
|-----------|---------------|----------------|----------------|-------------|---------------|
|-----------|---------------|----------------|----------------|-------------|---------------|

No

25. Additional comments regarding your report:

Successful applications for grant funding to support activities has mean that there has been some growth in the IRL team supporting this work